BLTE$158.05
Chart
Performance
Key Stats
AI BLTE Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralBelite Bio Inc. shows mixed signals with a promising profile in a growing therapeutic area, but faces challenges with profitability and a somewhat weak technical outlook. Investment requires careful consideration of the risk-reward balance.
Thematic
Belite Bio operates in the high-growth area of gene therapy for rare eye diseases, with a lead candidate in Phase 3 trials. The focus on unmet medical needs in ophthalmology aligns with strong thematic tailwinds in biotechnology and personalized medicine.
Fundamental
Belite Bio Inc. currently exhibits no revenue and consistent net losses, a common trait for clinical-stage biotechs. While cash reserves are significant, the lack of profitability and revenue presents a substantial risk.
Technical
Belite Bio's stock shows mixed technical signals. While some indicators suggest potential oversold conditions and a possible bounce, the overall trend across multiple timeframes appears bearish, with most moving averages indicating selling pressure.
| Factor | Score |
|---|---|
| Biotechnology Growth | 85 |
| Clinical Trial Progress | 80 |
| Unmet Medical Needs | 90 |
| Pipeline Diversity | 50 |
| Regulatory Landscape | 70 |
| Factor | Score |
|---|---|
| Valuation | 0 |
| Profitability | 0 |
| Growth | 0 |
| Balance Sheet Health | 95 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Support & Resistance | 60 |
| Oversold Indicators | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Cash Position
The company ended its latest quarter with $31.677 million in cash equivalents, indicating a healthy liquidity position.
Low Debt
The company has minimal debt, with only $537,000 in debt as of the latest quarter, indicating a low leverage risk.
Bearish Points (10)
Negative Earnings
The company has consistently reported negative EPS and net income, with an EPS of -1.36 TTM and a net loss of -33.056 million TTM, indicating unprofitability.
No Revenue and High P/E
The company has zero reported revenue, making P/E and P/S ratios meaningless or extremely high (-60.5 TTM P/E), suggesting the valuation is based on future potential rather than current performance.
Calendar
August 2025
9
Next Earnings Date
H: $-0.30
A: $-0.39
L: $-0.48
Profile
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Seasonals
Price Target
85.00 USD
The 39 analysts offering 1 year price forecasts for BLTE have a max estimate of 110.00 and a min estimate of 50.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
A global pharmaceutical leader with a strong oncology division, including Keytruda, making it a major competitor and potential partner in the immunotherapy space.
Weight: 94
A global pharmaceutical company with a significant and growing oncology pipeline, including strong presence in breast cancer treatments, making it a direct competitor and potential collaborator.
Weight: 93
A major pharmaceutical company with a substantial oncology presence, including recent acquisitions in the cancer therapy space, positioning it as a significant competitor or potential strategic partner.
Weight: 92
A leading pharmaceutical company with an expanding oncology portfolio focused on targeted therapies and immunotherapies, making it a relevant competitor and potential partner.